AC Immune (ACIU) Stock Price, Quote, News & History | Benzinga

AC Immune SA (ACIU) Stock Price, Quote, News & History

ACIUNASDAQ

Trade with Public

Trade with Public

$2.90

0.269.85%

At close: Aug 21, 5:00 PM EST

$2.83

-0.0699-2.41%

After Hours: Aug 21, 4:43 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$2.66

Close

$2.90

Volume / Avg.

442.01K / 253.15K

Day Range

$2.65 - $2.95

52 Wk Range

2.03 - 4.00

Market Cap

$288.03M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

69

Short Interest

7.28%

Days to Cover

18.18

Recent AC Immune SA News

AC Immune Says Early Data from Anti-Inflammatory Drug Gives Wider Clinical Momentum for Pipeline

AC Immune reports favorable interim Phase 1 results for ACI-19764, an oral NLRP3 inhibitor showing strong safety and brain penetration.

Vandana Singh

FGI Industries, Nouveau Monde Graphite And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Dow futures down 0.1%. FGI Industries (NASDAQ: FGI) reported mixed results for Q4, with losses of 29 cents per share beating estimates but sales missing. Stock down 7.8% in pre-market. Other stocks moving lower in pre-market: BBGI, MFI, JTAI, RMIX, TMCR, NMG, SHMD, ANL, CABA, FUFU.

Avi Kapoor

AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's

AC Immune reports Phase 2 data showing stabilized Parkinson's biomarkers, strong antibody response, and a potential slowing of disease progression in early-stage patients.

Vandana Singh

S&P 500 Moves Lower; US Crude Oil Inventories Increase

Avi Kapoor

AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients

AC Immune reports interim results from Phase 2 trial of ACI-7104.056 active immunotherapy for early Parkinson's disease.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-50.49M

Investing Cash Flow (TTM)

53.22M

Financing Cash Flow (TTM)

-373.00K

Free Cash Flow (TTM)

-51.09M

Capital Expenditure (TTM)

-594.00K

Net Change in Cash (TTM)

2.35M

Analyst Trends and Forecast

1

Mar

1

May

2

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$199.23M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

12.48

PB Ratio (TTM)

6.09

Earnings Yield % (TTM)

-19.97%

Earnings Yield % (FWD)

-22.64%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.44

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$958.00K

Total Cash

$27.76M

Debt to Equity

0.12

Issuance of Debt (TTM)

-$958.00K

Repayment of Debt (TTM)

-$958.00K

Key Statistics

Open

$2.66

Close

$2.90

Volume / Avg.

442.01K / 253.15K

Day Range

$2.65 - $2.95

52 Wk Range

2.03 - 4.00

Market Cap

$288.03M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

69

Short Interest

7.28%

Days to Cover

18.18

About

Sector

Health Care

Industry

Biotechnology

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, des...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy AC Immune (ACIU) stock?

A

You can purchase shares of AC Immune (NASDAQ:ACIU) through any online brokerage.

View our list of the best stock brokerages

Q

Who are AC Immune (ACIU) competitors?

A

Other companies in AC Immune’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for AC Immune (ACIU) stock?

A

AC Immune has a consensus price target of $10.00.

Q

What is the current price for AC Immune (ACIU)?

A

The stock price for AC Immune (NASDAQ: ACIU) is $2.8301 last updated August 21, 2026 at 4:43 PM EDT.

Q

Does AC Immune (ACIU) pay a dividend?

A

There are no upcoming dividends for AC Immune.

Q

When is AC Immune (NASDAQ:ACIU) reporting earnings?

A

AC Immune does not have any upcoming earnings scheduled.

Q

Is AC Immune (ACIU) going to split?

A

There is no upcoming split for AC Immune.

Q

What sector and industry does AC Immune (ACIU) operate in?

A

AC Immune is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.